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COX-2 inhibitor lumiracoxib (400 mg once daily [od]) has com-
parable efficacy to indomethacin (50 mg three times daily [tid])
for the treatment of acute flares of gout. Secondary analysis of
safety and tolerability included a specific, pre-defined comparison
of differences in blood pressure.
Methods: This was a 1-week, multicentre, randomized, double-
blind, double-dummy, active-controlled, parallel-group study of
lumiracoxib 400 mg od (n=118) vs indomethacin 50 mg tid
(n=117) (safety population) in patients with acute flares of gout.
The primary analysis was a test of non-inferiority in the per
protocol population of the mean change from baseline in pain
intensity in the study joint over Days 2-5.
The blood pressure profile was assessed by a pre-defined anal-
ysis of the mean change from baseline for systolic and diastolic
blood pressure.
Results: In the per protocol population, lumiracoxib 400 mg od
(n=112) was non-inferior to indomethacin 50 mg tid (n=110).
Least square mean (LSM) change from baseline in pain intensity
for lumiracoxib was 1.29 (1.47) vs 1.29 (1.50) over Days 2-5
(Days 2-7) treatment period for lumiracoxib and indomethacin,
respectively. Both drugs were also comparable in all secondary
efficacy assessments.
50% of the patients had a medical history of hypertension.
The table below shows the mean change from baseline in BP
for lumiracoxib vs indomethacin at study end, after 7 days of
treatment (safety population*).
Mean change/(SD) Lumiracoxib Indomethacin Two sided T-test
400 mg od n=114 50 mg tid n=116 p-value
Systolic blood
pressure (mmHg) -1.0 (9.74) 2.5 (10.68) 0.009
Diastolic blood
pressure (mmHg) -1.3 (6.06) 0.5 (6.57) 0.028
*Only patients with BP measurement at both baseline and study end were in-
cluded.
None of the patients in the lumiracoxib group showed a clinically
relevant increase in blood pressure (defined as change from
baseline of at least 25%), as compared to 1.7% of patients in the
indomethacin group.
Only 1.7% of the patients on lumiracoxib 400 mg od discontinued
study drug compared with 8.5% on indomethacin 50 mg tid. AEs
were reported in 10.2% of patients in the lumiracoxib group
compared with 22.2% of patients in the indomethacin group. Due
to suspected Good Clinical Practice non-compliance, a post-
hoc sensitivity analysis was performed after database closure
excluding a center containing 8 patients. The sensitivity analysis
revealed no substantial change of the study results, the only
exception was diastolic blood pressure (p=0.057).
Conclusions: Lumiracoxib 400 mg od is effective in the treat-
ment of acute gout with efficacy comparable to indomethacin
50 mg tid. In addition, even after short-term treatment, lumira-
coxib shows a favourable blood pressure profile as compared to
indomethacin, and with fewer AEs and discontinuations. Lumira-
coxib may thus provide an alternative effective treatment option
for acute gout.
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Purpose: To determine if there is an association between the
severity of ectopic bone formation after hip replacement surgery,
chronic hip pain and physical disability.
Methods: HIPAID was a double-blind randomised placebo-
controlled clinical trial conducted in 20 orthopaedic surgery cen-
tres in Australia and New Zealand.
902 patients undergoing elective primary or revision total hip re-
placement surgery were randomly allocated to 14 days treatment
with ibuprofen (1200mg daily) or matching placebo commenced
within 24 hours of surgery. Participants were required to have hip
radiographs, complete self-reported questionnaires measuring of
pain and physical function (WOMAC), report analgesia use and
undergo several physical performance measures (hip flexion, up
and go, 50ft walk time) six to twelve months after surgery.
Results: Hip radiographs were obtained from 798 (88%) par-
ticipants and scored for ectopic bone formation severity using
the Brooker grading (0-4). Among the 294 (37%) of HIPAID par-
ticipants with radiographic evidence of ectopic bone formation,
108 (37%) had at least moderate severity (Brooker grade 2, 3
or 4). Brooker grade 3 and 4 demonstrated increased pain and
function scores, compared with less severe grades of ectopic
bone formation; however this trend was not significant. There
were was also a trend in the physical performance measures,
but again this trend was not significant.
Ectopic bone formation and clinical outcomes
Brooker Grade Pain (0-10) Function (0-10)
mean (sd) mean (sd)
0 0.97 (1.47) 1.56 (1.57)
1 0.99 (1.49) 1.43 (1.57)
2 0.97 (1.57) 1.87 (1.79)
3 and 4 1.25 (1.85) 2.23 (1.95)
Conclusions: These data, from the largest-ever trial of pro-
phylaxis against ectopic bone formation, suggest that only a
small proportion of patients undergoing elective hip replacement
surgery will develop clinically relevant ectopic bone around the
new hip implant.
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Purpose: With the increased controversy associated with long-
term use of NSAIDs and COX-2 inhibitors, there is renewed
interest in the use of intraarticular (IA) injections, including
hyaluronans (HA), for the management of patients with knee os-
teoarthritis (OA). Non-animal stabilized hyaluronic acid (NASHA;
Durolane®) is administered as a single IA injection for OA of
the knee, and has an extended IA residence time (half-life: 4
